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Abstract
Malignant fibrous  histiocytoma (MFH) is one of the most common types of soft tissue sarcomas  in adults. The most
common location of MFH are the extremities and the trunk, with the most common site for distant metastases being the
lung. We describe a case with multiple synchronous sites of myxoid MFH but no lung metastases and presence of abnormal-
ities of 19p13.
Introduction
Malignant fibrous histiocytoma (MFH) is one of the
most  common  types  of  soft  tissue  sarcomas  in
adults,1,2 with the majority of tumors arising in the
trunk or the extremities. About 30–40% of patients
with MFH develop distant metastases, with the most
common site being the lung.3–7 Metastatic disease in
the absence of lung metastases is highly unusual. This
report describes a case in which a patient had multi-
ple synchronous myxoid MFH tumors without evi-
dence of lung metastases. We believe that the patient
had  multiple primary  sites  of  myxoid  MFH,  thus
raising the possibility of a genetic abnormality that
could predispose such a patient to develop multiple
sites of the same tumor. The description of the tumor
karyotype in the case of our patient is provided.
Case report
The patient was a 67-year-old man who originally
noticed a lump in his right calf area 3 years previ-
ously.  Magnetic  resonance  imaging  at  that  time
confirmed a tumor in the right calf, and a core needle
biopsy revealed high-grade myxoid malignant fibrous
histiocytoma  (MFH)  (Fig.  1).  The  patient  was
treated  with  neoadjuvant  chemotherapy  (mesna,
doxorubicin, ifosfamide and dacarbazine) and under-
went tumor resection followed by adjuvant radiation.
He remained well until 2 years later when he noticed
two 10-cm lumps in the upper right thigh and pain in
the epigastric area. A computerized tomography scan
of the abdomen performed at that  time revealed a
gastric mass, and the patient underwent excision of
the two thigh tumors followed by partial gastrectomy.
The pathology from all three sites was reviewed and
revealed high-grade myxoid MFH in each of them
(Figs. 2 and 3). The surgical margins of the two thigh
lesions resected were negative. The CD117  (c-kit)
stains performed on the partial gastrectomy specimen
were  negative.  The  patient  remained  well  for  3
months, when he presented to our institution with a
rapidly enlarging mass on the right forearm. Staging
CT  scans  preoperatively  revealed  no  evidence  of
pulmonary  or  abdominal  metastasis  and  patient
underwent wide excision of the right forearm lesion,
which  again  turned  out  to  be  high-grade  myxoid
MFH.
Cytogenetic analysis was performed on the fresh
samples from the right forearm excision. An abnor-
mal  clone with  complex  cytogenetic  abnormalities
was  observed,  that  had  the  following  hypodiploid
karyotype: 39,  der(X;6)idic(6)(q12)t(6;8)(p23;q13)
t(X;6)(p22.1;p23),-Y,-1,der(1)t(1;15)(p31;q13),der
(3;9)t(3;9)(p26;q34)add(9)(p24), i(4)(p10),der(6)
t(2;6)(q31;q27)ins(6;?)(q27;?),add(7)(q32),der(7)
t(7;?11)(q36;q21)ins(7;?)(q36;?),-8, -8,-10,del(11)
(p11.1p15.5),-13,-13,+14,der(14) t(3;14)(p21;
q32),-15,der(15)t(15;?22)(p11.2;q11.2),-17,-17,-
18,ins(18;?)(p11.2;?),add(19)(p13.1),del(19)
(p13.2p13.3),+22,del(22)(q13.1q13.3),der(22)del52 J. H. Muler et al.
(22)(p11.1p13)del(22)(q12q13),+ mar 1, + mar 2, +
mar 3.
Discussion
Malignant fibrous histiocytoma (MFH) is considered
to be one of the most common types of soft tissue sar-
comas in adults, accounting for 36–40% of all soft
tissue sarcomas analyzed in two large series.1,2 The
majority of MFH arise in the proximal extremities or
the trunk.2–4 The incidence of MFH increases with
age, with the majority of patients being over 50 years
of  age.4  The  local  recurrence  rate  for  MFH  is
28–51%  depending on whether adjuvant  radiation
was  used.2–6  The  rate  of  distant  metastasis  varies
from  30  to  46%.2,3,5,7  The  most  common site  of
distant  metastasis  was  by  far  the  lung  (63–91%),
followed by lymph nodes (10%) and bone (3–8%),
taken as a proportion of all metastatic sites.3,4,7 Table
1 illustrates the overall survival (OS) and disease-free
survival  (DFS)  for  MFH  from  various  reported
series:
Fig. 1. H&E stain right calf biopsy, ×200.
Fig. 2. H&E stain right thigh resection, ×400.Myxoid MFH with multiple primaries 53
A number of prognostic factors have been exam-
ined in terms of their predictive significance for over-
all  survival  and  recurrence  in  MFH  by  various
investigators, in an attempt to better define different
prognostic variables in this diverse group of soft tissue
sarcomas (Table 2).
There are four major variants of MFH recognized
today:  storiform-pleomorphic (the most common),
myxoid, giant cell and inflammatory.9 The myxoid
type  of  MFH  (also  known  as  myxofibrosarcoma)
accounts for about a third of all MFH cases.2,9 This
subtype  of  MFH  was  first  described  by  several
authors in the late 1970s, and was based on its dis-
tinct gelatinous appearance grossly, with a variable
amount of  myxoid stroma adjacent  to  the  cellular
areas microscopically.10–12
The median age at diagnosis of myxoid MFH is 65
years13 with peak incidence at 60–69 years.11 The
most common primary site was the extremities (77%),
the trunk (15%) and the retroperitoneum (8%).13 In
70% of cases, the primary tumor was subcutaneous at
presentation.13 It has been argued that the myxoid
type represents a distinct subgroup of MFH based on
its  better  prognosis  compared  to  the  other  MFH
Fig. 3. H&E stain mass from partial gastrectomy, ×400.
Table 1. Overall and disease-free survival in MFH
Ref. OS at 5 years
(%)
DFS at 5 years
(%)
Median follow-up
(months)
4 67.2 50.6 73
5 58 36 42
7 36 NA 72
8 70 NA 36
Abbreviations: OS, overall survival; DFS, disease-free survival.
Table 2. Significant prognostic factors in MFH
Factor Outcome influenced Ref.
Tumor size MFS, OS 2,3,4,5,7,8
Subtype: myxoid versus non-myxoid MFS, DSS, OS 2,3,8
Tumor necrosis MFS, OS 2,8
UICC Stage III+IVA DSS 3
Deep tumor location DSS 3,6
Age > 50 DSS 3
Grade MFS, OS 3,4,5
Negative margins after primary resection LRFS, DFS, OS 3,5,7
Abbreviations: MFS, metastasis free survival; DSS, disease-specific survival; OS, overall survival; DFS, disease-free
survival; LRFS, local recurrence-free survival.54 J. H. Muler et al.
variants.12 The reported rates of recurrence vary from
52 to 66%.11,13 Metastasis occurred in 23–35% of
cases, with the most common site of metastasis being
the lungs, followed by the lymph nodes, skeleton and
liver.11,13 Mentzel et al. have described a low-grade
variant of myxofibrosarcoma, with an even lower inci-
dence of distant metastasis.14 Within this group, the
authors described five cases in which the low-grade
myxofibrosarcoma tended to  become progressively
higher grade with each recurrence.14
Factors  that  are  believed  to  favorably  influence
recurrence  rates  and  metastasis  in  myxoid  MFH
include:  small  size,  superficial  location,  increased
proportion  of  the  myxoid  component  and  low
grade.11,14  In  the  original  Scandinavian  series  on
myxoid MFH, the 5- and 10-year survival rates were
65 and 52%, respectively.13 Histological grade, type
of surgical therapy, tumor size, age, and interval to
first recurrence were important predictors for survival
and recurrence.13
The case reported here has an unusual feature, in
that the patient may have had what we believe to be
multiple new primary sites of MFH in locations such
as soft tissues of the extremities, without evidence of
metastases to the lung parenchyma.
There are two possible explanations for such an
unusual  clinical  course.  It  is  conceivable  that  the
reason our patient did not have lung metastases is
because the multiple recurrences represent separate
myxoid MFH primary sites. The superficial location
of the patient’s lesions would place him at a lower risk
for distant metastases, as superficial location of the
tumor  had  a  higher  local  recurrence  rate  but  a
decreased incidence of distant metastases compared
to  the  deep  lesions.3,6,11  Myxoid  MFH  primary
tumors have  been known to  present as  superficial
lesions in  up to  70%  of  cases.13,14  An  alternative
explanation  is  that  the  patient  developed multiple
subcutaneous metastases over the clinical course of
the disease. Coincidental second primary tumors pre-
viously described with myxoid MFH include: palmar
fibromatosis, lipomas, basal cell carcinomas of the
skin, carcinomas of the large bowel and stomach, and
carcinomas of the ovary and uterus.13 However, only
one case in the early original series on myxoid MFH
described  a  patient  with  multiple  synchronous
tumors on the arm, buttock and shoulder.11
The absence of ring chromosomes and the presence
of 19p+ marker in our case would be consistent with
an increased relapse rate, both locally and distally, and
would  support  the  distant  metastases  point  of
view.20,21
None  of  the  above  arguments disprove that  the
multiple  lesions  could  have  represented  distant
metastases. After all, our myxoid MFH lesions were
high grade with a small myxoid component, a finding
associated with  a 24–31% rate  of  distant  metasta-
sis.11 However, such a pattern  without pulmonary
involvement  is  highly  unusual.  An  early  series on
myxoid MFH described two patients with a similar
clinical course of multiple subqutaneous recurrences
and  involvement  of  the  GI  tract.10  Both  patients
developed pulmonary metastases, while the patient in
our case did not.
Despite its being one of the most common types of
soft  tissue  sarcomas  in  many  published  clinical
series,  the  validity  of  classifying  certain  types  of
MFH as separate histopathological entities has been
questioned.15,16  In  a  recent  study  by  Fletcher
et al.,17  of  61  cases  initially  labeled  as  storiform–
pleomorphic MFH, all but one case was reclassified
using predefined histopathological criteria proposed
by the authors. Myxoid MFH (myxofibrosarcoma)
on the other hand, remained the most common sub-
type  in  that  series.  Thus,  it  appears  that  myxoid
MFH  is  one  subtype  of  MFH  that  represents  a
distinct reproducible entity.18
Advances  in  various  techniques  of  chromosomal
analysis have prompted many investigators to try and
define MFH on a more basic molecular level. The ear-
lier studies revealed a clonal chromosomal abnormality
in 17 out of 25 cases of MFH, with further observation
that the presence of an abnormal 19p+ marker chromo-
some was associated with increased frequency of local
recurrence.19–21  Breakpoints  in  1q11,  1p36,  3p12,
11p11 and 19p13 were frequently observed.19 Another
group reported two cases with sole abnormalities of
t(5;7)(q31;q22) and der(13;14)(q10;q10), raising the
possibility  that  they  represent  primary  cytogenetic
abnormalities.22 Using the technique of comparative
genomic hybridization, investigators in one study were
able to demonstrate that gain of 7q32 was associated
with decreased metastasis-free survival and overall sur-
vival, whereas gain of 1p31 was associated with a trend
towards decreased overall survival.23
The  cytogenetic  findings  in  our  case  revealed
abnormalities of 19p13 for both of the homologues
that were present, an abnormality reported to have
adverse prognostic significance with increased rates
of recurrence and metastasis.19–21 A trend towards
fewer relapses in tumors with ring chromosomes was
noted in one of the series.21 Of note, no ring chromo-
somes were found in our case. Previously reported
abnormalities  also  found  in  our  case  include:
presence of hypodiploid clone, abnormality of 9p and
11p11,  and  presence  of  dicentric  chromosomes
der(X;6), der(3;9) are dicentric.
Several candidate genes implicated in the patho-
genesis of MFH have been recently identified. Fre-
quent amplification in the region of 8p23.1 in eight
out of 14 MFHs has led one group of investigators to
identify a novel gene MASL1 located in this narrow
region.24 The product of this gene is believed to be an
ATP/GTP-binding protein involved in the regulation
of the cell cycle. Frequent loss of region 13q12–q14
and 13q21, reported in 78% of MFHs analyzed in
one series, led the authors to believe that mutation or
inactivation of the RB1 tumor suppressor gene couldMyxoid MFH with multiple primaries 55
be an initial event in the pathogenesis of MFH.25,26
Mutations of TP53 tumor suppressor gene were also
demonstrated in series on MFH.27,28 Finally, pres-
ence of  a  shared  deletion of  9p21  between  a  rare
inherited form of MFH and sporadic MFH indicated
that the tumor suppressor genes present in that loca-
tion CDKN2A/B could contribute to tumorigenesis
in  MFH.29  This  hypothesis  is  supported  by  one
recent study, which identified frequent loss of 9p21
leading to the deletion of the CDKN2A gene in up to
55% of MFH cases analyzed.28
Of note, however, no single cytogenetic or molec-
ular rearrangement exists that has been shown to be
pathognomonic of MFH. It has been argued that the
broad range of complex rearrangements frequently
reported with MFH stems from the possibility that the
cases represent groups of heterogeneous sarcomas.22
In conclusion,  we report a case of myxoid MFH with
possibly multiple primary sites, absence of pulmonary
metastases and presence of an abnormality of 19p13.
This, in turn, raises the possibility of a yet undeter-
mined germ line mutation specific for MFH in such
a patient, that could account for the development of
multiple primary sites of the same tumor. It also dem-
onstrates that within the spectrum of MFH, subgroups
of patients may have a distinct clinical course based
on  the  different molecular pathogenesis  of  certain
types of MFH. Further studies aimed at determining
the  exact  cellular  aberrations  associated  with  this
neoplasm and their clinical significance are warranted.
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